MA26926A1 - Procede d'obtention de formulations aqueuses de principes actifs sensibles a l'oxydation. - Google Patents

Procede d'obtention de formulations aqueuses de principes actifs sensibles a l'oxydation.

Info

Publication number
MA26926A1
MA26926A1 MA26990A MA26990A MA26926A1 MA 26926 A1 MA26926 A1 MA 26926A1 MA 26990 A MA26990 A MA 26990A MA 26990 A MA26990 A MA 26990A MA 26926 A1 MA26926 A1 MA 26926A1
Authority
MA
Morocco
Prior art keywords
active ingredients
aqueous formulations
sensitive active
oxidation sensitive
obtaining aqueous
Prior art date
Application number
MA26990A
Other languages
English (en)
Inventor
Daniele Fredj
Francois Dietlin
Original Assignee
Pharmatop Scr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8851012&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA26926(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmatop Scr filed Critical Pharmatop Scr
Publication of MA26926A1 publication Critical patent/MA26926A1/fr

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D19/00—Degasification of liquids
    • B01D19/0005—Degasification of liquids with one or more auxiliary substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Removal Of Specific Substances (AREA)
MA26990A 2000-06-06 2003-01-03 Procede d'obtention de formulations aqueuses de principes actifs sensibles a l'oxydation. MA26926A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0007231A FR2809619B1 (fr) 2000-06-06 2000-06-06 Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention

Publications (1)

Publication Number Publication Date
MA26926A1 true MA26926A1 (fr) 2004-12-20

Family

ID=8851012

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26990A MA26926A1 (fr) 2000-06-06 2003-01-03 Procede d'obtention de formulations aqueuses de principes actifs sensibles a l'oxydation.

Country Status (16)

Country Link
US (1) US6992218B2 (fr)
CN (1) CN1556694A (fr)
AP (1) AP1880A (fr)
AU (1) AU2001266120A1 (fr)
CA (1) CA2415403C (fr)
CZ (1) CZ200313A3 (fr)
DZ (1) DZ3384A1 (fr)
FR (1) FR2809619B1 (fr)
MA (1) MA26926A1 (fr)
MX (1) MXPA03000001A (fr)
NZ (1) NZ523458A (fr)
PE (1) PE20030508A1 (fr)
RU (1) RU2003100090A (fr)
TW (1) TWI237570B (fr)
WO (1) WO2001093830A1 (fr)
YU (1) YU103A (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2809619B1 (fr) * 2000-06-06 2004-09-24 Pharmatop Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention
ITMI20012135A1 (it) 2001-10-16 2003-04-16 Bioren S A Soluzioni iniettabili pronte all'uso di paracetamolo
FR2832063B1 (fr) * 2001-11-15 2004-08-27 Aguettant Lab Procede de production de solutions stables de substances phenoliques et les solutions en resultant
FR2851164B1 (fr) 2003-02-14 2005-04-22 Xuan Tho Nguyen Formulation liquide injectable de paracetamol
US20050020554A1 (en) * 2003-06-06 2005-01-27 Ahmed Salah U. Stability of hormone formulations
FR2880807B1 (fr) * 2005-01-19 2007-04-13 Aguettant Sa Lab Composition pharmaceutique injectable
DK1848431T3 (en) 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
DE102005037653A1 (de) * 2005-08-05 2007-02-15 Theraselect Gmbh Stabile, flüssige Formulierung von Paracetamol
US20070077303A1 (en) * 2005-09-30 2007-04-05 Azaam Alli Methods for providing oxidatively stable ophthalmic compositions
FR2894154B1 (fr) * 2005-12-06 2008-03-14 Pharmatop Scr Nouveau procede de stabilisation de substances minerales ou organiques sensibles a l'oxydation.
WO2007092620A2 (fr) * 2006-02-09 2007-08-16 Macusight, Inc. Formulations stables et leurs procedes de preparation et d'utilisation
KR101520408B1 (ko) 2006-03-23 2015-05-14 산텐 세이야꾸 가부시키가이샤 혈관 투과성-관련 질환 또는 상태를 위한 제형 및 방법
US20070249727A1 (en) 2006-04-21 2007-10-25 The Proctor & Gamble Company Compositions and kits useful for treatment of respiratory illness
US10022339B2 (en) 2006-04-21 2018-07-17 The Procter & Gamble Company Compositions and methods useful for treatment of respiratory illness
AU2006346318B2 (en) 2006-07-18 2011-02-10 Genfarma Laboratorio S.L. Injectable liquid paracetamol formulation
EP1992334A1 (fr) * 2007-05-08 2008-11-19 Docpharma NV/SA Formule stable pour le stockage de médicament phénolique sensible à l'oxydation, spécialement le paracétamol, et qui comprend une solution de médicament aqueuse désoxygénée par le processus de fabrication à température contrôlée de la formule
DE102007026975A1 (de) * 2007-06-01 2008-12-04 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt Antioxidationsmittel für Lebensmittel
AR067048A1 (es) * 2007-06-18 2009-09-30 Combino Pharm Sl Formulaciones acuosas de acetaminofen para inyeccion.
AR067047A1 (es) * 2007-06-18 2009-09-30 Combino Pharm Sl Formulaciones acuosas de acetaminofen para inyeccion.
CA2705733C (fr) 2007-11-13 2015-02-03 Cadence Pharmaceuticals Acetaminophene par voie intraveineuse en dose reduite
WO2009098716A2 (fr) * 2008-01-17 2009-08-13 Aptuit Laurus Private Limited Compositions pharmaceutiques aqueuses stables
FR2926992B1 (fr) * 2008-02-06 2011-01-14 Moly Pharma Formulation d'une solution de paracetamol injectable,procede de preparation et de conditionnement d'une telle solution et dispositif de conditionnement d'une telle solution
US20110097470A1 (en) * 2008-06-11 2011-04-28 Joerg Kowalczyk Highly active antioxidant based on trehalulose
EP2243477A1 (fr) 2009-04-22 2010-10-27 Fresenius Kabi Deutschland GmbH Paracétamol destiné à l'administration parentérale
EP2464332B1 (fr) 2009-08-13 2016-03-02 Neogen N.V. Formulation de paracétamol en solution aqueuse stable en stockage
US8404748B2 (en) * 2009-08-13 2013-03-26 Neogen N.V. Storage-stable formulation of paracetamol in aqueous solution
WO2011036712A1 (fr) * 2009-09-24 2011-03-31 株式会社 東芝 Solution absorbant le dioxyde de carbone gazeux
US20120245230A1 (en) 2009-12-10 2012-09-27 Tecnimede-Sociedade Tecnico- Medicinal, S.A. Method and composition for preparing stable liquid formulations of paracetamol
US20110207824A1 (en) * 2010-02-25 2011-08-25 Moly Pharma Formulation of an injectable paracetamol solution, method for preparing and packaging such a solution and device for packaging such a solution
AU2011359032A1 (en) * 2011-02-10 2013-08-29 Neogen N.V. Storage-stable formulation of paracetamol in aqueous solution
EP3685827A1 (fr) 2011-03-04 2020-07-29 Grünenthal GmbH Formulation pharmaceutique aqueuse de tapentadol pour administration orale
ES2414557B1 (es) * 2012-01-16 2014-06-10 Novocat Farma, S.A. Composición acuosa de paracetamol para inyección
ITMI20121154A1 (it) 2012-06-29 2013-12-30 Sint Sa Soluzione iniettabile di acetaminofene per la somministrazione spinale
CN103006550A (zh) * 2012-12-11 2013-04-03 哈药集团三精制药股份有限公司 一种胞磷胆碱钠注射液及其制备方法
US20140303254A1 (en) * 2013-04-08 2014-10-09 InnoPharma Licensing LLC Process Of Manufacturing A Stable, Ready To Use Infusion Bag For An Oxidation Sensitive Formulation
UY35988A (es) * 2014-02-27 2015-09-30 Sint Sa Proceso para la producción de una solución inyectable de noradrenalina de baja concentración
BR102014005885B1 (pt) 2014-03-13 2021-04-13 Biotec Biológica Indústria Farmacêutica Ltda E.P.P Formulação farmacêutica líquida injetável estável de paracetamol em bolsa plástica pronta para uso
WO2016008546A1 (fr) * 2014-07-18 2016-01-21 Everbright Pharmaceuticals S.A.R.L. Formulation aqueuse comprenant du paracétamol et de l'ibuprofène
CN104288099B (zh) * 2014-09-25 2017-02-15 西安仁仁药业有限公司 一种布洛芬注射液的制备方法
PT3479823T (pt) * 2015-03-27 2020-09-29 Gruenenthal Gmbh Formulação estável para administração parentérica de tapentadol
RS62844B1 (sr) 2015-06-18 2022-02-28 Estetra Srl Orodisperzibilna dozna jedinica koja sadrži komponentu estetrola
MY195019A (en) 2015-06-18 2023-01-03 Estetra Sprl Orodispersible dosage unit containing an estetrol component
EP3120837A1 (fr) 2015-07-22 2017-01-25 Stada Arzneimittel Ag Solution de bortezomib prêts à l'emploi
SI3411004T1 (sl) 2016-02-05 2021-08-31 Innopharma, Inc. Postopek proizvajanja stabilne vrečke za infuzijo za pripravek, občutljiv na oksidacijo, ki je pripravljen na uporabo
US10898452B2 (en) 2016-09-23 2021-01-26 Gruenenthal Gmbh Stable formulation for parenteral administration of Tapentadol
CA3051467C (fr) 2017-01-30 2022-11-29 Nevakar, Inc Compositions de norepinephrine et procedes associes
WO2018192664A1 (fr) * 2017-04-20 2018-10-25 Hyloris Developments Sa Procédé de préparation d'une composition à faible teneur en oxygène dissous, comprenant de l'acétaminophène, et éventuellement un ou plusieurs ains, et une composition obtenue à partir de celui-ci
WO2019150381A1 (fr) * 2018-02-01 2019-08-08 Joshi Mahendra R Composition pharmaceutique stable et procédé de production d'une injection de chlorhydrate d'isoprotérénol
JOP20200260A1 (ar) 2018-04-19 2019-10-19 Estetra Sprl مركبات واستخداماتها للتخفيف من الأعراض المصاحبة لانقطاع الطمث
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
CR20200552A (es) 2018-05-16 2021-05-13 Bayer Healthcare Llc Fórmula de suspención de alta concentración para medicamentos en cápsula de gel blanda paae resfriado y gripe
EP3863589A1 (fr) * 2018-10-08 2021-08-18 Merz Pharma GmbH & Co. KGaA Flacon pré-rempli de neurotoxine
US10478453B1 (en) 2019-01-15 2019-11-19 Exela Pharma Sciences, LLC Stable, highly pure L-cysteine compositions for injection and methods of use
CN113105040A (zh) * 2021-04-02 2021-07-13 武汉工控工业技术研究院有限公司 一种自然水体无菌处理及长期保存技术
CN116803376B (zh) * 2023-08-04 2024-02-13 广州白云山星群(药业)股份有限公司 一种复方愈创木酚磺酸钾口服溶液的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3443004A (en) * 1965-04-08 1969-05-06 Ciba Geigy Corp Injectable solution containing 6-chloroor 6-trifluoromethyl-7-sulfamyl - 1,2,4-benzothiodiazine-1,1-dioxide diuretic
DD153578A1 (de) * 1980-10-22 1982-01-20 Hans Meffert Stabilisierung von oxydationsempfindlichen wirkstoffen,vorrangig dithranol in arzneizubereitungen
RO93391B (ro) * 1984-12-20 1988-03-31 Eli Lilly And Company Procedeu pentru prepararea unor saruri de dobutamina
AU5405894A (en) * 1992-10-21 1994-05-09 Alcon Laboratories, Inc. Composition for irrigating intraocular tissues and maintaining mydriasis during intraocular surgery
AU5680994A (en) * 1992-12-10 1994-07-04 Abbott Laboratories Stabilized catecholamine solutions
FR2740338B1 (fr) * 1995-12-01 1997-12-05 Rhone Poulenc Rorer Sa Compositions pharmaceutiques stabilisees contenant de la dobutamine
FR2751875B1 (fr) * 1996-08-05 1998-12-24 Scr Newpharm Nouvelles formulations liquides stables a base de paracetamol et leur mode de preparation
FR2809619B1 (fr) * 2000-06-06 2004-09-24 Pharmatop Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention

Also Published As

Publication number Publication date
CZ200313A3 (cs) 2003-11-12
MXPA03000001A (es) 2004-03-19
CN1556694A (zh) 2004-12-22
FR2809619B1 (fr) 2004-09-24
AP1880A (en) 2008-08-19
US20040054012A1 (en) 2004-03-18
DZ3384A1 (fr) 2001-12-13
TWI237570B (en) 2005-08-11
CA2415403C (fr) 2011-05-24
US6992218B2 (en) 2006-01-31
RU2003100090A (ru) 2004-05-10
PE20030508A1 (es) 2003-06-25
YU103A (sh) 2006-05-25
FR2809619A1 (fr) 2001-12-07
NZ523458A (en) 2005-08-26
CA2415403A1 (fr) 2001-12-13
WO2001093830A1 (fr) 2001-12-13
AP2002002711A0 (en) 2002-12-31
AU2001266120A1 (en) 2001-12-17

Similar Documents

Publication Publication Date Title
MA26926A1 (fr) Procede d'obtention de formulations aqueuses de principes actifs sensibles a l'oxydation.
DZ2744A1 (fr) Distribution d'un agent actif aérosolé.
BR0104326B1 (pt) ôcomposição aquosa de revestimentoö.
FR2814380B1 (fr) Poudre de microcapsules et procede d'obtention
ES2189989T3 (es) Desinfectante de lavado para desinfeccion higienica y quirurgica de las manos.
BR0109650A (pt) 3-cianoquinolinas, 3-ciano-1,6-naftiridinas e 3-ciano-1,7-naftiridinas como inibidores da cinase proteìca
HUP0000979A1 (hu) FK-506 jelű vegyületet és származékait tartalmazó gyógyászati készítmények
IL151609A0 (en) Process to prepare aqueous formulations of pesticides
ATE285462T1 (de) Reinigungsmittel enthaltend chitosan
AU2002364044A1 (en) Ultrasound sensing of concentration of methanol's aqueous solution
IT1319240B1 (it) Procedimento per la oligomerizzazione selettiva dell'etilene.
MA25917A1 (fr) Derives d'acides propionique ayant des proprietes activantes de ppar-alpha.
HK1063290A1 (en) Pharmaceutical formulations containing low concentrations of peroxide for treating or preventing vaginal infections.
ATE309220T1 (de) Substituierte 1,2,3,4-tetrahydrochinolin-2- carbonsäurederivate
IT1318514B1 (it) Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
FR2678836B1 (fr) Formulations pour voie orale d'ubidecarenone sous la forme de solutions aqueuses.
DZ3340A1 (fr) Procede pour l'hydroxylation de composes aliphatiques
BR9812982A (pt) Agente anti-reumático
EP1304036A4 (fr) Insecticides
NO20001658L (no) Stabil vandig oppløsning av EM 12
FR2779346B1 (fr) Procede d'obtention d'un principe actif anti-radicalaire et photoprotecteur, principe actif obtenu, composition cosmetique
IT1318674B1 (it) Faramaci per l'incontinenza.
IL146694A (en) Use of an aqueous solution containing a biologically active complex of tellurium dioxide for manufacturing a medicament
DK1413575T3 (da) Fremgangsmåde til fremstilling af derivater af (1,5-diaryl)pyrazol-3-ylpropansyre
WO2001085147A3 (fr) Formulations stabilisees de 6-hydroxy-3-(4-[2-(piperidin-1-yl) ethoxy]phenoxy)-2-(4-methoxyphenyl) benzo[b]thiophene et sels de ces composes